Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

被引:10
作者
Tong, Yan [1 ]
Huang, Jian Qing [1 ]
Chen, Yang [1 ]
Tu, Mei [1 ]
Wang, Wei [1 ]
机构
[1] Fujian Med Univ, Longyan Affiliated Hosp 1, Longyan, Fujian, Peoples R China
关键词
liraglutide; sitagliptin; bowel preparation quality; gastrointestinal discomfort; gastrointestinal motility; DOSE POLYETHYLENE-GLYCOL; GLUCOSE; COLONOSCOPY; EXENATIDE; SUPERIOR; MOTILITY; TRANSIT;
D O I
10.3389/fphar.2023.1176206
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM). Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group (n = 120), sitagliptin group (n = 120), and control group (n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety. Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant (p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups (p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025). Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis
    Jin, Yuxin
    Zhao, Hang
    Hou, Yilin
    Song, Guangyao
    ACTA DIABETOLOGICA, 2020, 57 (10) : 1129 - 1144
  • [22] Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials
    Tran, Susan
    Retnakaran, Ravi
    Zinman, Bernard
    Kramer, Caroline K.
    DIABETES OBESITY & METABOLISM, 2018, 20 : 68 - 76
  • [23] Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell, Sheila A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (03) : 371 - 377
  • [24] Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus
    Makri, Evangelia
    Kita, Marina
    Goulas, Antonis
    Papaioannidou, Paraskevi
    Efstathiadou, Zoe A.
    Adamidou, Fotini
    Polyzos, Stergios A.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (06) : 1913 - 1919
  • [25] Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study
    Bea, Sungho
    Son, Heejun
    Bae, Jae Hyun
    Cho, Sun Wook
    Shin, Ju-Young
    Cho, Young Min
    DIABETES OBESITY & METABOLISM, 2024, 26 (01) : 108 - 117
  • [26] Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide
    Karhust, Martin L.
    Bronden, Andreas
    Roder, Michael E.
    Leotta, Salvatore
    Sonnet, David P.
    Knop, Filip K.
    GASTROENTEROLOGY, 2019, 157 (02) : 569 - 571
  • [27] Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats
    Fang, Jidong
    Miller, Patti
    Grigson, Patricia S.
    BRAIN RESEARCH BULLETIN, 2023, 192 : 142 - 155
  • [28] Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series
    Lajthia, Estela
    Bucheit, John D.
    Nadpara, Pramit A.
    Dixon, Dave L.
    Caldas, Lauren M.
    Murchie, Michael
    Sisson, Evan M.
    PHARMACY PRACTICE-GRANADA, 2019, 17 (04):
  • [29] Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes
    Ogawa, Susumu
    Ishiki, Mikihito
    Nako, Kazuhiro
    Okamura, Masashi
    Senda, Miho
    Mori, Takefumi
    Ito, Sadayoshi
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 223 (02) : 133 - 135
  • [30] ALBIGLUTIDE Glucagon-Like Peptide GLP-1 Receptor Agonist Treatment of Type 2 Diabetes
    Rosenstock, Julio
    Stewart, Murray W.
    DRUGS OF THE FUTURE, 2010, 35 (09) : 701 - 712